Benefit from our expertise and unique properties of κλ bodies
We aim at working with partners to develop truly human bispecific antibodies in different therapeutic areas.
Several collaborative models are possible, depending on the partner’s objectives, needs and expertise.
We can provide access to the technology, generate the bispecifc leads for our partner or further develop them if they fall into our expertise in the immuno-oncology space such as CD47 targeting and CD28 targeting.
We are looking forward to discussing your projects and ideas with you. Contact us.
